(Q45423656)

14 December 2017

title

Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer (English)

1 reference

14 December 2017

1 reference

1 reference

William P Tew

1

1 reference

14 December 2017

publication date

1 March 2013

1 reference

Current Treatment Options in Oncology

14 December 2017

published in

1 reference

14 December 2017

volume

14

1 reference

14 December 2017

issue

1

1 reference

14 December 2017

page(s)

1-11

1 reference

Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden.

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Cancer in older persons: an international issue in an aging world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Ovarian cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

The management of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Lung cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Weekly topotecan in the management of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Experience with bevacizumab in the management of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Resource utilization for ovarian cancer patients at the end of life: how much is too much?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Variations in the Use of Chemotherapy for Elderly Patients With Advanced Ovarian Cancer: A Population-Based Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Intraperitoneal chemotherapy in older women with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0219-Z

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

21 January 2018

1 reference

12 December 2020

Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.

1 reference

12 December 2020

Is the easier way ever the better way?

1 reference

12 December 2020

Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients

1 reference

12 December 2020

Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany

1 reference

12 December 2020

The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study

1 reference

12 December 2020

What is the role of neoadjuvant chemotherapy in the management of ovarian cancer?

1 reference

12 December 2020

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

1 reference

12 December 2020

Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study

1 reference

12 December 2020

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

1 reference

12 December 2020

Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment

1 reference

12 December 2020

Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)

1 reference

12 December 2020

Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer

1 reference

12 December 2020

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

1 reference

12 December 2020

10.1007/S11864-012-0219-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

14 December 2017

1013136528

0 references

1 reference